|20th October 2020||Holdings A/S Novo||2,414,563||Conversion of derivative||$0.00|
|20th October 2020||Holdings A/S Novo||150,000||Open or private purchase||$18.00||$2,700,000.00|
|20th October 2020||Holdings A/S Novo||737,071||Conversion of derivative||$0.00|
|20th October 2020||Holdings A/S Novo||200,000||Open or private purchase||$15.00||$3,000,000.00|
|20th October 2020||Holdings A/S Novo||2,442,080||Conversion of derivative||$0.00|
|15th October 2020||Holdings A/S Novo||450,000||Open or private sale||$11.00||$4,950,000.00|
|14th October 2020||Holdings A/S Novo||250,000||Open or private purchase||$15.00||$3,750,000.00|
|14th October 2020||Holdings A/S Novo||4,739,336||Conversion of derivative||$0.00|
|18th September 2020||Investments, Lp Rtw||750,000||Open or private purchase||$17.00||$12,750,000.00|
|18th September 2020||Investments, Lp Rtw||1,535,131||Conversion of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Milestone Pharmaceuticals, Inc. is a biopharmaceutical company. It designs and develops a rapid-onset nasal spray with Etripamil.